AcouSort (ACOU) Q2 2024 earnings summary

Executive summary

• Werfen launched a point-of-care diagnostics system using AcouSort's patented acoustofluidic technology, marking a major milestone in diagnostics.

• New collaborations were initiated in cell therapy (US and Europe) and flow cytometry, expanding OEM opportunities.

• Participation in high-profile conferences and selection for EU-funded projects increased AcouSort's visibility and innovation pipeline.

Financial highlights

• Q2 2024 net sales were TSEK 961, down from TSEK 1,816 in Q2 2023; total income for the quarter was SEK 1,993 thousand (3,362).

• Result before tax for Q2 2024 was TSEK -4,714 (Q2 2023: -3,193); EPS was SEK -0.32 (-0.24).

• Cash and cash equivalents at June 30, 2024, were TSEK 16,683 (11,889); equity ratio was 61% (58%).

• Operating expenses remained stable, with personnel costs at TSEK -4,375 (-4,447) and other external expenses at TSEK -2,234 (-2,457).

Outlook and guidance

• Focus remains on expanding OEM partnerships in diagnostics, cell therapy, and flow cytometry, with expectations of future revenue growth as collaborations mature.

• Efforts to boost cash flow include intensified sales of benchtop systems and strategic collaborations with key opinion leaders.

• Continued external validation and commercialization of AcouTrap for exosome and extracellular vesicle processing are planned.